<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200417</url>
  </required_header>
  <id_info>
    <org_study_id>19-371</org_study_id>
    <nct_id>NCT04200417</nct_id>
  </id_info>
  <brief_title>Chemoembolization for Lung Tumors</brief_title>
  <official_title>Phase I Study of Transarterial Chemoembolization of Lung Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine if it is safe to perform lung chemoembolization and if
      the lung chemoembolization procedure can successfully deliver chemotherapy to lung tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">December 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant toxicity will be evaluated according to CTCAE v5.0</measure>
    <time_frame>Up to 12 months post treatment</time_frame>
    <description>Safety will be evaluated by participant toxicity according to CTCAE v5.0</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lung Metastases</condition>
  <condition>Endobronchial Metastases</condition>
  <condition>Pleural Metastases</condition>
  <condition>Mediastinal Metastases</condition>
  <arm_group>
    <arm_group_label>Lung, Endobronchial, Mediastinal or Pleural Metastases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will have unresectable and unablatable lung, endobronchial, mediastinal, or pleural metastases (from any primary) that are not responding to chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chemoembolization</intervention_name>
    <description>Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.</description>
    <arm_group_label>Lung, Endobronchial, Mediastinal or Pleural Metastases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Mitomycin (5mg/m^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.</description>
    <arm_group_label>Lung, Endobronchial, Mediastinal or Pleural Metastases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipiodol</intervention_name>
    <description>Mitomycin (5mg/m^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.</description>
    <arm_group_label>Lung, Endobronchial, Mediastinal or Pleural Metastases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Embospheres</intervention_name>
    <description>Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.</description>
    <arm_group_label>Lung, Endobronchial, Mediastinal or Pleural Metastases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lung, endobronchial, pleural, or mediastinal metastases that are not responding to
             systemic chemotherapy, and that are not amenable to ablation, resection, or SBRT.

          -  At least 18 years old.

          -  ECOG performance status 0 or 1

        Exclusion Criteria:

          -  Primary lung cancer

          -  &gt;50% of a lung is replaced with tumor

          -  Oxygen saturation &lt;92% on room air

          -  FEV1 &lt;60%

          -  Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, MRI, or direct
             pressure measurement)

          -  Recent pulmonary embolism (within 3 months)

          -  Pulmonary arteriovenous malformation

          -  Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1
             month)

          -  Symptomatic heart failure (dyspnea, volume overload)

          -  Left bundle branch block (contraindication to pulmonary angiography)

          -  Renal failure (eGFR &lt;30 mL/min/1.73m^2)

          -  Pregnancy

          -  Breastfeeding

          -  Altered mental status that would interfere with consent or follow-up

          -  Platelets &lt; 100,000 (after transfusion, if needed)

          -  INR&gt;2 (after transfusion, if needed)

          -  Hemoglobin &lt;7 (after transfusion, if needed)

          -  Hyperthyroidism (contraindication to lipiodol)

          -  Planned radioactive iodine imaging or therapy (contraindication to lipiodol)

          -  Allergy to lipiodol or mitomycin

          -  Allergy to iodinated contrast that can not be treated with steroid / diphenhydramine
             premedication

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the investigational product or interpretation of subject safety or study
             results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F. Edward Boas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>F. Edward Boas, MD, PhD</last_name>
    <phone>212-639-2536</phone>
    <email>boasf@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Solomon, MD</last_name>
    <phone>212-639-5012</phone>
    <email>solomons@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Consent only)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Edward Boas, MD, PhD</last_name>
      <phone>212-639-2536</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Commack (Consent Only)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Edward Boas, MD, PhD</last_name>
      <phone>212-639-2536</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Consent only)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Edward Boas, MD, PhD</last_name>
      <phone>212-639-2536</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Edward Boas, MD, PhD</last_name>
      <phone>212-639-2536</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable Lung Cancer</keyword>
  <keyword>Unresectable Endobronchial Mestastases</keyword>
  <keyword>Unresectable Pleural Metastases</keyword>
  <keyword>Unresectable Mediastinal Metastases</keyword>
  <keyword>Lung Chemoembolization</keyword>
  <keyword>19-371</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

